List of Velphoro drug patents

Velphoro is owned by Vifor Fresenius.

Velphoro contains Ferric Oxyhydroxide.

Velphoro has a total of 22 drug patents out of which 0 drug patents have expired.

Velphoro was authorised for market use on 27 November, 2013.

Velphoro is available in tablet, chewable;oral dosage forms.

Velphoro can be used as control of phosphorous levels in patients.

The generics of Velphoro are possible to be released after 26 May, 2035.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10933090 VIFOR FRESENIUS Pharmaceutical compositions
Nov, 2028

(5 years from now)

US11013762 VIFOR FRESENIUS Pharmaceutical compositions
Nov, 2028

(5 years from now)

US10925896 VIFOR FRESENIUS Pharmaceutical compositions
Nov, 2028

(5 years from now)

US10682376 VIFOR FRESENIUS Pharmaceutical compositions
Nov, 2028

(5 years from now)

US10925897 VIFOR FRESENIUS Pharmaceutical compositions
Nov, 2028

(5 years from now)

US11013761 VIFOR FRESENIUS Pharmaceutical compositions
Nov, 2028

(5 years from now)

US10695367 VIFOR FRESENIUS Pharmaceutical compositions
Nov, 2028

(5 years from now)

US11013762

(Pediatric)

VIFOR FRESENIUS Pharmaceutical compositions
May, 2029

(6 years from now)

US10925896

(Pediatric)

VIFOR FRESENIUS Pharmaceutical compositions
May, 2029

(6 years from now)

US10925897

(Pediatric)

VIFOR FRESENIUS Pharmaceutical compositions
May, 2029

(6 years from now)

US10933090

(Pediatric)

VIFOR FRESENIUS Pharmaceutical compositions
May, 2029

(6 years from now)

US10682376

(Pediatric)

VIFOR FRESENIUS Pharmaceutical compositions
May, 2029

(6 years from now)

US11013761

(Pediatric)

VIFOR FRESENIUS Pharmaceutical compositions
May, 2029

(6 years from now)

US10695367

(Pediatric)

VIFOR FRESENIUS Pharmaceutical compositions
May, 2029

(6 years from now)

US9561251 VIFOR FRESENIUS Pharmaceutical compositions
Jan, 2030

(6 years from now)

US9561251

(Pediatric)

VIFOR FRESENIUS Pharmaceutical compositions
Jul, 2030

(7 years from now)

US11446252 VIFOR FRESENIUS Pharmaceutical composition, comprising phosphate binder particles
Nov, 2034

(11 years from now)

US11234938 VIFOR FRESENIUS Pharmaceutical composition, comprising phosphate binder particles
Nov, 2034

(11 years from now)

US10624855 VIFOR FRESENIUS Pharmaceutical composition, comprising phosphate binder particles
Nov, 2034

(11 years from now)

US10624855

(Pediatric)

VIFOR FRESENIUS Pharmaceutical composition, comprising phosphate binder particles
May, 2035

(12 years from now)

US11446252

(Pediatric)

VIFOR FRESENIUS Pharmaceutical composition, comprising phosphate binder particles
May, 2035

(12 years from now)

US11234938

(Pediatric)

VIFOR FRESENIUS Pharmaceutical composition, comprising phosphate binder particles
May, 2035

(12 years from now)

Drugs and Companies using FERRIC OXYHYDROXIDE ingredient

Market Authorisation Date: 27 November, 2013

Treatment: Control of phosphorous levels in patients

Dosage: TABLET, CHEWABLE;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in